0001437749-26-016751
SEC filingRevenue accelerated 52% YoY to $1.3M from higher EsoGuard test consideration, driving operating and net loss reductions of 3% and 48%, yet negative gross margins and $12.3M free cash burn highlight commercialization timing challenges.
Gross profit was negative $369 thousand, or -29.4% of revenue, as the Company incurs test-related expenses in the period activities occur, while revenue recognition may lag into subsequent periods. Management highlights this timing mismatch as a key driver of quarterly margin variability, consistent with the diagnostic services business model where costs precede cash inflows from payers and patients.
Net loss improved 48.3% to $13.9 million from $26.9 million, with diluted EPS at -$0.17 versus -$0.52—a 67.3% enhancement. These gains stem from the operating loss reduction, underscoring progress toward breakeven despite high fixed costs in early-stage diagnostics.